XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 178,700,434 $ 22,196,097
Short-term investments 158,535,744 67,338,017
Accounts receivable 7,692,944 700,073
Accounts receivable from affiliated entities 501,311 1,332,044
Prepaid expenses and other current assets 31,563,697 1,584,598
Prepaid expenses and other current assets from affiliated entities 70,543 1,050,140
Total current assets 377,064,673 94,200,969
Fixed assets, net 11,190,521 12,773,017
Investment in affiliated entities 4,154,049 6,315,356
Investment in Geneos 957,567 0
Intangible assets, net 3,283,540 3,693,851
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 13,008,571 13,783,009
Other assets 17,641,755 2,672,024
Total assets 437,814,047 143,951,597
Current liabilities:    
Accounts payable and accrued expenses 23,533,298 18,237,258
Accounts payable and accrued expenses due to affiliated entities 794,928 729,729
Accrued clinical trial expenses 5,841,180 4,049,727
Deferred revenue 77,878 92,353
Deferred revenue from affiliated entities 0 31,775
Operating lease liability 2,264,261 2,074,842
Grant funding liability 8,616,622 6,065,212
Grant funding liability from affiliated entities 135,000 708,425
Total current liabilities 41,263,167 31,989,321
Deferred revenue, net of current portion 82,927 101,567
Derivative liability 0 8,819,023
Operating lease liability, net of current portion 18,669,643 20,409,922
Deferred tax liabilities 32,046 32,046
Grant funding liability from affiliated entity, net of current portion 37,500 135,000
Other liabilities 39,776 36,943
Total liabilities 113,813,932 138,546,739
Stockholders’ equity:    
Preferred stock 0 0
Common stock 167,527 101,361
Additional paid-in capital 1,205,842,585 742,646,785
Accumulated deficit (881,858,432) (739,785,655)
Accumulated other comprehensive income (loss) (247,834) 472,608
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 323,903,846 3,435,099
Non-controlling interest 96,269 1,969,759
Total stockholders’ equity 324,000,115 5,404,858
Total liabilities and stockholders’ equity 437,814,047 143,951,597
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 49,537,210 64,180,325
Convertible bonds    
Current liabilities:    
Convertible debt $ 4,151,663 $ 12,842,592